EDX Medical Group plc (LSE:EDX) is a Cambridge-based developer of digital diagnostic products and services aimed at personalised treatment for cancer, heart disease and infectious diseases. Founded by life sciences entrepreneur Professor Sir Christopher Evans and chief executive Dr Mike Hudson, the company moved …
Abingdon Health plc (LSE:ABDX) is an international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech. Specialising in lateral flow technology, it takes customer projects from concept to routine manufacturing. The group is headquartered in York, with laboratories in Doncaster and …
The latest interim results showed revenue growth, higher gross margins and narrower operating losses, supported by manufacturing improvements and cost discipline. Liquidity remained substantial but declined as operations consumed cash. Commercial progress in clinical and biopharmaceutical workflows contrasted with weaker activity in China. A …
SkinBioTherapeutics plc (LSE:SBTX) is an AIM-quoted life science company focused on skin health. It develops products based on its SkinBiotix microbiome platform, sells the AxisBiotix range of food supplements and owns the Dermatonics foot-care brand. It has also expanded into contract manufacturing through an …
Halma plc (LSE:HLMA) is in focus as investors weigh company fundamentals against a changing UK market backdrop. For the FTSE 100, the broader setting on 22 October 2026 includes renewed sensitivity to inflation, bond yields, interest-rate expectations and corporate earnings. That environment can produce …
The most useful lens for International Biotechnology Trust PLC is the interaction between clinical trial catalysts and company-specific execution. On 22 October 2026, investors assessing London-listed shares face a market shaped by persistent inflation, the prospect of tighter monetary policy and uneven sector demand. …
The most useful lens for Biotech Growth Trust PLC is the interaction between drug development sentiment and company-specific execution. On 22 October 2026, investors assessing London-listed shares face a market shaped by persistent inflation, the prospect of tighter monetary policy and uneven sector demand. …
The latest available trading communication highlighted strategic progress, a lower operating cost base and continued clinical and commercial activity. Management maintained confidence in annual guidance at that update. These developments support recovery interest in the core technology, but adoption must be assessed through repeat …
The relevant market is London’s AIM growth market. Inclusion in the AIM market does not itself establish membership of a benchmark index or a positive share-price move.
The principal identifiable area of investor interest is partnering and development progress. This is a focus area, not confirmation that a fresh price-moving announcement occurred today.